You are here: Home » Companies » News
Business Standard

Sun Pharma gets USFDA nod for generic drug to treat cardiac problems

As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017

Press Trust of India  |  New Delhi 

MNCs raise concerns around the definition of inventions, provisions for compulsory licensing
Representative image

Industries on Thursday said its subsidiary has received approval from the US health regulator to market a generic version of GSK's Coreg CR, extended-release capsules in the American market.

One of the company's wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for the generic product in strengths of 10mg, 20mg, 40mg and 80 mg, Sun Pharma said in a statement.

Coreg CR extended-release capsules are indicated for treating various heart conditions, including heart failure and high blood pressure.

As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017.

Sun Pharma shares were trading 2.32 per cent up at Rs 535.40 apiece on BSE today.

First Published: Thu, October 26 2017. 15:38 IST
RECOMMENDED FOR YOU